Colonics
About Me
Recent Posts
- 'Personality Genes' May Help Account For Longevity
- 4 Mushroom Poisonings In 2 Weeks - Doctors Test Milk Thistle As Treatment
- Improved Diagnostics For Sleeping Sickness
- Prostate Growth May Be Slowed By Statins
- New Tools For Psychological Science Research - Facebook And Smartphones
Menu
Calendar
| Mon | Tue | Wed | Thu | Fri | Sat | Sun |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 | |||
Friends
Links
Entry 1 of 2381
Last Page | Next Page
2/19/2008
-
MabCampath Available For First Line Treatment Of B-Cell Chronic Lymphocytic Leukaemia (CLL) For Whom Fludarabine Chemotherapy Is Not Appropriate
|
Bayer Schering Pharma (BSP) and Genzyme Corporation, keep quiet the availability of MabCampath® (alemtuzuma More: - Read the rest here |
Post A Comment! :: Send to a Friend! |
for the first-line treatment of career with B-CLL for whom fludarabine combination chemotherapy is not appropriate.[i] MabCampath was long ago approved for the treatment of B-CLL in chosen work who have been already treated with alkylating agents and have failed fludarabine therapy.Share and enjoy
